All Guidance
Advanced hormone-dependent prostate cancer with spinal metastases - to be read in conjunction with the SPC
Denosumab 120mg injection - Prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.
Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Denosumab 60mg injection - Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of bone loss
associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture
Denosumab as a second-line treatment option for the prevention of Osteoporotic Fragility Fractures
The purpose of this guideline is to assist primary care practitioners to advise patients of the appropriate monitoring regimen for their clinical condition and diabetes type and to ensure appropriate volumes of testing strips are supplied.
This information sheet has been produced to summarise key information about insulin Toujeo for those providing care for patients on this insulin, including on-going prescribing, supply or administration. It is not specifically intended for diabetes specialists who are responsible for initiation and switching to/from insulin Toujeo®. Specialists are advised to refer to the SPC and local protocols for further information.
LSCMMG have developed a menopause product relative price list to be used in conjunction with the LSCMMG primary care management of menopause guideline - available below.
Please note: GPs and other primary care prescribers are under no obligation to act upon the advice issued by a private specialist. If the NHS prescriber receiving the request does not believe they have the competence to initiate or continue the recommended intervention a referral to an appropriate NHS specialist should be made. Patients are entitled to receive additional private care if this is provided separately from NHS care.
To be read in conjunction with NICE TA64, NICE TA188 and SPC.
For hypogonadism due to testosterone deficiency in adult men
Indication (licensed):Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.
Unlicensed indication: As supplementation for postmenopausal women with low sexual desire if HRT alone is not effective.
Further patient information is available via the RCOG menopause hub: https://www.rcog.org.uk/for-the-public/menopause-and-later-life/
Prescribing Information Sheet: To be read in conjunction with the relevant SPCs
Please note: NHSE has stated that GICs should retain responsibility for providing prescriptions and for monitoring until the GP has agreed to a transfer of responsibilities. Individual prescribers MUST only prescribe within their own level of competence
Prescribing Information Sheet: To be read in conjunction with the relevant SPCs
Please note: NHSE has stated that GICs should retain responsibility for providing prescriptions and for monitoring until the GP has agreed to a transfer of responsibilities. Individual prescribers MUST only prescribe within their own level of competence